CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
Authors
A Borg
B Tetu
+48 more
BA Gusterson
C Carlomagno
C Charpin
C Wright
CC Benz
CW Elston
D Karunagaran
D M Barnes
D W Miles
DC Allred
DJ Slamon
DJ Slamon
DM Barnes
DM Barnes
DR Ciocca
EMJJ Berns
FG Kern
FP O’Malley
GA Niehans
H Yamauchi
IL Andrulis
J Baselga
JC Newby
JGM Klijn
JL Hayward
K Leitzel
K Leitzel
L Coussens
LM Witters
M Saceda
MF Press
MF Press
O Stal
P Smith
PM Ravdin
R D Rubens
R Kath
RD Rubens
RJ Pietras
RJB King
RM Elledge
S J Houston
S Sjogren
SG Archer
T A Plunkett
T Kuukasjarvi
T Manni
WJ Gullick
Publication date
Publisher
Nature Publishing Group
Doi
Cite
View
on
PubMed
Abstract
The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-erbB2 by immunohistochemistry. c-erbB2 was overexpressed in 76 (32%) of primary breast cancers and did not correlate with any other prognostic factor. The overall response to treatment and time to progression were significantly lower in patients with c-erbB2-positive tumours compared to those that were c-erbB2-negative (38% vs 56%, P = 0.02; and 4.1 months vs 8.7 months, P < 0.001, respectively). In multivariate analysis, c-erbB2 status was the most significant predictive factor for a short time to progression (P = 0.0009). In patients with ER-positive primary tumours treated at relapse with tamoxifen (n = 170), overexpression of c-erbB2 was associated with a significantly shorter time to progression (5.5 months vs 11.2 months, P < 0.001). In conclusion, overexpression of c-erbB2 in the primary tumour is an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer. In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine therapy. © 1999 Cancer Research Campaig
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 03/12/2019